Ultragenyx Pharmaceutical Inc. (RARE) Stock Forecast & Predictions

Ultragenyx Pharmaceutical Inc. RARE: $108.87

60 Leveroni Ct, Novato, California, US. | Sector: Manufacturing | Exchange: NASDAQ/NGS (GLOBAL SELECT MARKET) | Web: https://www.ultragenyx.com/

  • Market Cap$7.31B
  • Change (52 Weeks)69.13%
  • Low (52 Weeks)$57.1
  • Ultragenyx Pharmaceutical Inc. (RARE) Forecast Based on Technical Analysis


    Neutral
    Based on 16 Technical Indicators where 18.75% are on Buy, 31.25% on Sell, and 50.00% Neutral.

    According to the market data, Ultragenyx Pharmaceutical Inc. (RARE) stock price is $108.87 and the 52 weeks low is $57.1, which means the Ultragenyx Pharmaceutical Inc. stock price is up 69.13% in the last 12 months.

    Ultragenyx Pharmaceutical Inc. (RARE) Stock Price has been Trending Strongly with an ADX reading of 25.07 as per the Weekly Chart.

    A Upward trend indicates that Ultragenyx Pharmaceutical Inc. (RARE) Stock Price may keep going up, with temporary Retracement (the process of stock price bouncing because of short term profit taking by the traders and investors).

    Technical Indicators are algorithms that are used mostly by Technical traders to predict the price action of a stock.

    Based on our analysis of 16 technical indicators, 18.75% are indicating that RARE Stock price might rise further, 31.25% indicating that RARE Stock price might fall, and 50.00% are in a neutral position.

    Based on these technical algorithms, overall RARE stock price has a Neutral Signal, which means the stock price has the potential to move either up or down, depending on the nature of consolidating market phase, since majority of indicators are providing a neutral signal.

    Ultragenyx Pharmaceutical Inc. (RARE) Stock Forecast By Analysts


    On Hold
    Analysts Recommendations for Ultragenyx Pharmaceutical Inc. (RARE) is based on 23 Institutional Analyst Ratings where 34.78% are on Strong Buy, 26.09% on Moderate Buy, 39.13% remains on Hold, 0.00% are on Moderate Sell and 0.00% are on Strong Sell.

    Out of 23 Institutional Analysts, majority recommended RARE stock as On Hold. This means investors are recommended to hold their existing positions if any, otherwise, the recommendation is neither to buy nor sell at this stage. Since most investors and traders follow analyst ratings closely, this can be a potentially driving factor for the future stock price of Ultragenyx Pharmaceutical Inc..

    Ultragenyx Pharmaceutical Inc. (RARE) Stock Price Prediction By Analysts


    HighLowAverage
    $204.75$80.80$157.97
    $157.9745.1% Upside
    Updated: 2021-04-22 00:00:00

    The Average Price target for RARE set by the institutional analysts is $157.97 where High Estimate is $204.75, Median $171.87 and Low $80.80.

    The average price target for RARE by Institutional Analysts is $157.97, which is 45.1% Upside from the current price. So according to the Institutional Analysts, RARE Stock might be a bit undervalued at this stage and there’s potential for upside.

    However, although Institutional Analysts set their price targets after extensive research, they’re not always correct. After all, the market is mostly driven by investors speculation and emotion than just concrete numbers.

    Ultragenyx Pharmaceutical Inc. (RARE) Stock Forecast Based on News Sentiment


    Neutral
    Based on 3 articles published Last Week, where 50.00% are Bullish and 50.00% are Bearish.

    According to the news articles published last week, journalists and bloggers had a mixed sentiment of RARE consisting of positive and negative, it shows that Ultragenyx Pharmaceutical Inc. had a neutral news coverage.

    Neutral news coverage usually doesn't affect short-term price of a stock, so RARE stock price most likey won't have any reaction to last weeks news coverage.

    Ultragenyx Pharmaceutical Inc. (RARE) Stock Forecasts By Institutional Analysts


    Analyst
    Recommendation
    Action
    Morgan StanleyOverweightMaintained
    SVB LeerinkOutperformMaintained
    Piper SandlerOverweightMaintained
    JP MorganNeutralDowngraded
    BarclaysOverweightMaintained
    Morgan StanleyOverweightMaintained
    WedbushNeutralDowngraded
    Evercore ISI GroupIn-LineReiterated
    Canaccord GenuityBuyMaintained
    SVB LeerinkOutperformMaintained
    Morgan StanleyOverweightMaintained
    B of A SecuritiesBuyMaintained
    Morgan StanleyOverweightMaintained
    Canaccord GenuityBuyMaintained
    Morgan StanleyOverweightMaintained
    Morgan StanleyOverweightMaintained
    Canaccord GenuityBuyMaintained
    Morgan StanleyOverweightMaintained
    Credit SuisseNeutralMaintained
    SunTrust Robinson HumphreyBuyMaintained
    StifelBuyMaintained
    CitigroupNeutralMaintained
    WedbushOutperformMaintained
    Morgan StanleyOverweightMaintained
    SunTrust Robinson HumphreyBuyMaintained
    Morgan StanleyOverweightMaintained
    CitigroupNeutralMaintained
    Morgan StanleyOverweightMaintained
    JMP SecuritiesMarket OutperformMaintained
    Morgan StanleyOverweightMaintained
    Morgan StanleyOverweightUpgraded
    CitigroupNeutralMaintained
    Raymond JamesMarket PerformDowngraded
    CitigroupNeutralUpgraded
    Raymond JamesOutperformMaintained
    WedbushOutperformMaintained
    SunTrust Robinson HumphreyBuyMaintained
    Credit SuisseNeutralMaintained
    CitigroupSellMaintained
    Bank of AmericaBuyMaintained
    WedbushOutperformMaintained
    WedbushOutperformMaintained
    BarclaysOverweightMaintained
    Canaccord GenuityBuyMaintained
    Leerink SwannOutperformMaintained
    Credit SuisseNeutralDowngraded
    BarclaysOverweightUpgraded
    Goldman SachsNeutralInitiated
    SunTrust Robinson HumphreyBuyUpgraded
    Stifel NicolausBuyMaintained
    Morgan StanleyEqual-WeightMaintained
    JP MorganOverweightMaintained
    Bank of AmericaBuyMaintained
    Evercore ISI GroupOutperformUpgraded
    Credit SuisseOutperformInitiated
    JefferiesBuyUpgraded
    Canaccord GenuityBuyMaintained
    BairdOutperformMaintained
    Morgan StanleyEqual-WeightMaintained
    WedbushOutperformUpgraded
    BarclaysEqual-WeightInitiated
    SunTrust Robinson HumphreyHoldDowngraded
    JMP SecuritiesMarket OutperformMaintained
    Canaccord GenuityBuyMaintained
    Evercore ISI GroupIn-LineInitiated
    BernsteinMarket PerformInitiated
    WedbushNeutralDowngraded
    H.C. WainwrightNeutralDowngraded
    JefferiesHoldDowngraded
    WedbushOutperformReiterated
    PiperJaffrayNeutralDowngraded
    CitigroupSellDowngraded
    PiperJaffrayOverweightInitiated
    Bank of AmericaBuyInitiated
    JMP SecuritiesMarket OutperformMaintained
    BairdOutperformInitiated
    JP MorganMarket OutperformMaintained
    Leerink SwannOutperformInitiated
    H.C. WainwrightBuyInitiated
    Credit SuisseOutperformMaintained
    Credit SuisseOutperformInitiated
    CitigroupNeutralUpgraded
    Canaccord GenuityBuyInitiated
    Canaccord GenuityBuyInitiated
    Stifel NicolausBuyInitiated
    JefferiesBuyInitiated
    Morgan StanleyEqual-WeightDowngraded
    JMP SecuritiesOutperformInitiated
    Canaccord GenuityBuyMaintained
    Canaccord GenuityBuyMaintained
    WedbushOutperformInitiated
    MLV & Co.BuyInitiated
    CRT CapitalBuyInitiated
    Canaccord GenuityBuyMaintained
    SunTrust Robinson HumphreyBuyInitiated
    JefferiesBuyInitiated
    BairdOutperformInitiated
    Morgan StanleyOverweightInitiated
    JP MorganOverweightInitiated
    Canaccord GenuityBuyInitiated

    Ultragenyx Pharmaceutical Inc. (RARE) Stock Earning Per Share (EPS) Forecast / Estimate


    $-1.290
    The average consensus EPS for RARE is $-1.290 with a high estimate of $-0.862 and Low of $-1.823 for the period 2021-06-30 and based on 18 Institutional Analysts.

    Last Quarter


    Actual
    Estimate
    Date
    $-1.13$-1.28380262020-09-30


    The latest average Earning Per Share Estimate for Ultragenyx Pharmaceutical Inc. is $-1.29, which is lower than RARE's last EPS, $-1.13. This means that Analysts are expecting Ultragenyx Pharmaceutical Inc. to report lower earnings. This can drive share prices lower since the investors have negative sentiment about market performance of Ultragenyx Pharmaceutical Inc..

    Earning Per Share (EPS) History


    Actual
    Estimate
    Date
    $-1.13$-1.28380262020-09-30
    $0.41$-1.574882020-06-30
    $-1.91$-1.71544620000000012020-03-31
    $-1.62$-1.68229620000000012019-12-31
    $-1.96$-1.71003000000000022019-09-30
    $-1.89$-1.73074622019-06-30
    $-1.82$-1.771742019-03-31
    $-1.73$-1.82567762018-12-31
    $-1.74$-1.995122018-09-30
    $-1.06$-2.12688359999999982018-06-30
    $-2.03$-0.1934432018-03-31
    $-1.89$-2.03215622017-12-31
    $-1.87$-1.89656762017-09-30
    $-1.72$-1.76168282017-06-30
    $-1.63$-1.740122017-03-31
    $-1.75$-1.758482016-12-31
    $-1.64$-1.55900882016-09-30
    $-1.46$-1.471352016-06-30
    $-1.35$-1.3187072016-03-31
    $-1.42$-1.16084162015-12-31
    $-1.03$-0.89079662015-09-30
    $-0.83$-0.64697582015-06-30
    $-0.63$-0.55462499999999992015-03-31
    $-0.52$-0.53768282014-12-31
    $-0.5$-0.46922014-09-30
    $-0.45$-0.42842014-06-30
    $-0.85$-0.38079662014-03-31
    $-4.98$-0.38762013-12-31

    What is Analyst Ratings & Price Targets?

    The analysts provide Buy, Sell or Hold ratings after extensive research of a companies financial reports, listening to conference calls and some of them even get in contact with upper management of the company to get an overall picture of operation.

    Although institutional Analyst’s are not always correct, their ratings are followed by millions of traders around the world and they can heavily influence trading activities for a company.

    As a retail investor, going through analyst ratings will instantly provide you an idea if the stock is worth buying. Top Analysts also provide their price targets. It’s a prediction of where the stock price might go based on their analysis.

    The best way to analyze price targets is to combined average price targets of major analysts. If the average price target is much higher than the current price of the stock, then the probability of a stock going up is also high.

    What is Technical Analysis?

    Technical Analysis refers to analyzing a stock's price over a period of time. In the financial market, past price patterns are one of the strongest indicators of an asset's future performance.

    In easier terms, millions of traders use Live Charts to watch the stock prices, it is actually a single source of truth for most traders. When a stock's price reaches a significant price level/pattern in the chart, millions of traders take buy/sell positions from those levels.

    As a regular investor, one of the easiest ways to check technical analysis of a stock is through Technical Indicators. Technical Indicators are programmed algorithms that monitor price changes in the Charts and indicate Buy/Sell based on market conditions.

    Some Technical Indicators can be very powerful (e.g SMA) and some can be pretty useless. Stock research tools like iTradely heavily simplify the technical analysis process for the investors by showing Buy/Sell/Neutral ratings combined from 17 powerful technical indicators, all in one page.

    What is Earnings Per Share (EPS) and Why is it Important?

    EPS, or Earning Per Share, can tell a lot about a stock’s performance. It’s calculated by dividing a company’s profit by the number of outstanding shares of its common stocks.

    In layman’s term, earnings is an indicator of a company’s profitability. Higher the earnings, the more profitable a company is.
    Some traders pick stocks solely based on EPS or earnings Analysis, it is a very powerful indicator of a stock’s price.

    Before you buy a stock, check the company’s earnings History and Surprises. A Surprise happens when a company reports a much higher or lower actual earnings/EPS than the forecasted earnings/EPS.

    If a company reports higher EPS surprises consistently, analysts keep raising their estimates, traders become more confident in the company, driving the share price higher.

    What is Stock Sentiment?

    Stock Sentiment refers to how people speculating about the stock or what kind of trading position investors are often taking.

    There are different kinds of sentiments you can find online for a company, this includes Investor Sentiment (Percentage of investors buying or selling), News Sentiment (Is the company getting positive or negative impressions from the Press?), Social Sentiment (The overall trends about the company in social media, is it negative or positive?).